Topical use of teprenone

• US 20090214607A1
• Filed: 05/12/2006
• Published: 08/27/2009
• Est. Priority Date: 05/13/2005
• Status: Abandoned Application

• Current Assignee: Sederma, Co.
• Original Assignee: Sederma, Co.
• Inventors: Lintner, Karl, Mas Chamberlin, Claire
• Application Number:
  US11/920,322
• Publication Number:
  US 20090214607A1
• Time in Patent Office: Days
• US Class Current: 424/401
• CPC Class Codes: A61K 31/121 acyclic
• CPC Class Codes: A61K 8/35 Ketones, e.g. benzophenone
• CPC Class Codes: A61P 17/16 Emollients or protectives, e.g. against radiation
• CPC Class Codes: A61Q 19/002 Aftershave preparations
• CPC Class Codes: A61Q 19/007 Preparations for dry skin
• CPC Class Codes: A61Q 19/08 Anti-ageing preparations

Abstract

Topical use of teprenone in a cosmetic or dermopharmaceutical composition as an active preventing and/or limiting the skin cells sénescence and/or protecting the general state of the skin.

Claims

1-17. -17. (canceled)

18. A method for preventing and/or limiting the senescence of skin cells, for protecting the general state of the skin, and/or for preventing and/or limiting the formation of reactive oxygen species (ROS) comprising topically applying a composition containing an effective amount of teprenone and a dermatologically acceptable carrier to the skin of a subject in need thereof.

19. The method of claim 18 wherein the amount of teprenone is sufficient to prevent and/or limit peroxidation of the cutaneous lipids and/or oxidation of proteins in skin cells of the skin of the subject.

20. The method of claim 18 wherein the amount of teprenone is sufficient to stimulate the synthesis of thioredoxin in skin cells of the skin of the subject.

21. The method of claim 18 wherein the amount of teprenone is sufficient to protect the catalase activity of skin cells of the skin of the subject.

22. The method of claim 18 wherein the amount of teprenone is sufficient to inhibit and/or limit the induction of stress biological markers Hsp 70 and Hsp 27 in skin cells of the skin of the subject.

23. The method of claim 18 wherein the amount of teprenone is sufficient to prevent and/or inhibit the release of pro-inflammatory cytokines IL8 and VEGF at skin cells level of the skin of the subject.

24. The method of claim 18 wherein the amount of teprenone is sufficient to inhibit and/or limit the replicative senescence and apoptosis of skin cells of the skin of the subject.

25. The method of claim 18 wherein the amount of teprenone is sufficient to promote the mechanisms of DNA and/or RNA protection and/or repair during skin cells mitosis of the skin of the subject.

26. The method of claim 18 wherein the amount of teprenone is sufficient to protect the telomeres of skin cell chromosomes of the skin of the subject.

27. The method of claim 18 wherein the amount of teprenone is sufficient to stimulate growth and/or differentiation of skin cells of the skin of the subject.

28. The method of claim 18 wherein the amount of teprenone is sufficient to promote the prenylation of skin cells proteins of the skin of the subject.

29. The method of claim 18 wherein the composition comprises 0.00001% (w/w) to about 50% (w/w) of teprenone from the total weight of the composition.

30. The method of claim 29 wherein the composition comprises 0.0001% (w/w) to 20% (w/w) of teprenone from the total weight of the composition.

31. The method of claim 30 wherein the composition comprises 0.001% (w/w) to about 10% (w/w) of teprenone from the total weight of the composition.

32. The method of claim 18 wherein the composition further comprises at least one skin care active or additional ingredient.

33. The method of claim 18 wherein the teprenone is used in the form of a solution, dispersion, emulsion, paste, or powder individually or as a premix in vehicles such as macro-, micro-, or nanocapsules, macro-, micro- or nanospheres, liposomes, oleosomes or chylomicrons, macro-, micro-, or nanoparticles or macro-, micro or nanosponges, micro or nano emulsions, or adsorbed on organic polymer powders, talcs, bentonites, or other inorganic or organic supports.

34. The method of claim 18 wherein the composition is in the form of a cream, lotion, ointment, milk, gel, emulsion, dispersion, solution, suspension, foam, varnish, stick, skin “

essence,”

serum, adhesive or absorbent material, transdermal patch, powder, oil, pomade, colloid, solid suspension, or pencil.

35. The method of claim 18 wherein said composition prevents and/or controls the signs of skin aging such as wrinkles and lines, bags, reduced sebum secretion and/or the increase in trans-epidermal water loss, the loss of skin firmness and/or elasticity and/or ptosis and/or cutaneous anisotropy, UV sunspots, erythrosis, the decrease in cutaneous microcirculation, the variation in epidermal and/or dermal thickness, and/or the decrease in skin softness, and/or the variation in the grain of the skin and/or the variation in pore size, and/or the variation in skin pH.

36. A method for preventing and/or limiting the senescence of skin cells, for protecting the general state of the skin, and/or for preventing and/or limiting the formation of reactive oxygen species (ROS) comprising topically applying a composition containing an effective amount of teprenone and a dermatologically acceptable carrier to the skin of a subject in need thereof wherein said composition contains 0.00001% (w/w) to about 50% (w/w) of teprenone from the total weight of the composition.

37. A cosmetic or dermopharmaceutical composition suitable for topical application to the skin comprising an amount of teprenone sufficient to prevent and/or limit the senescence of skin cells, to protect the general state of the skin, and/or to prevent and/or limit the formation of reactive oxygen species (ROS) of the skin, and a dermatologically acceptable carrier.

38. The cosmetic or dermopharmaceutical composition of claim 37 wherein the composition comprises 0.00001% (w/w) to about 50% (w/w) of teprenone from the total weight of the composition.

39. The cosmetic or dermopharmaceutical composition of claim 38 wherein the composition comprises 0.0001% (w/w) to 20% (w/w) of teprenone from the total weight of the composition.

40. The cosmetic or dermopharmaceutical composition of claim 37 wherein the amount of teprenone is sufficient to prevent and/or limit peroxidation of the cutaneous lipids and/or oxidation of proteins in skin cells of the skin of the subject.

41. The cosmetic or dermopharmaceutical composition of claim 37 wherein the amount of teprenone is sufficient to stimulate the synthesis of thioredoxin in skin cells of the skin of the subject.

42. A cosmetic or dermopharmaceutical composition suitable for topical application to the skin comprising an amount of teprenone sufficient to prevent and/or limit the senescence of skin cells, to protect the general state of the skin, and/or to prevent and/or limit the formation of reactive oxygen species (ROS) of the skin, and a dermatologically acceptable carrier, wherein the composition further comprises 0.00001% (w/w) to about 50% (w/w) of teprenone from the total weight of the composition and is in the form of a cream, lotion, ointment, milk, gel, emulsion, dispersion, solution, suspension, foam, varnish, stick, skin “

essence,”

serum, adhesive or absorbent material, transdermal patch, powder, oil, pomade, colloid, solid suspension, or pencil.